HOUSTON, TX--(Marketwire - July 14, 2009) - Bederra Corporation (PINKSHEETS: BEDA), a medical imaging and diagnostic Company, has signed a Letter of Intent to acquire Neogenex Medical Technologies, a Houston, TX based Technology, Development and Marketing company that focuses on Pain Therapies for Arthritis, Soft tissue and Joint applications.
Neogenex Medical Technologies, Inc. has rights to patents and technology to produce and market a low level laser device cleared by the FDA to treat arthritis pain and carpal tunnel syndrome. The company currently markets these FDA approved devices to medical professionals, Fitness Clubs and Corporate Wellness Facilities. More than 3500 medical professionals, therapists and trainers are currently using these devices as treatment options.
"The current market for these products and treatments is well over $10-15 Billion as more than 80 million people can utilize these therapies. Neogenex has already established itself in this market and would make a great addition to Bederra's growing line of products and services," stated Graham Williams, CEO of Bederra.
About Bederra Corp.
Bederra Corporation, through its wholly owned subsidiaries Diagnos, Inc. and Lumar Imaging, Inc., provides multiple modality diagnostic medical imaging services to the greater Houston area and the world famous Texas Medical Center. The Company's business strategy is to continue to expand its current operations and seek out additional acquisitions that will complement its core offerings.
Under The Private Securities Litigation Reform Act of 1995: The statements
in the press release that relate to the company's expectations with regard
to the future impact on the company's results from new products and
services in development, including any planned acquisitions, are
forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. The results anticipated by any or all of
these
forward-looking statements may not occur. The Company undertakes no
obligation to publicly release the result of any revisions to these
forward-looking statements that may be made to reflect events or
circumstances after the date hereof, or to reflect the occurrence of
unanticipated events or changes in the Company's plans or expectations.
